(DGX) Quest Diagnostics - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 21.749m USD | Total Return: 19% in 12m

Stock Medical Testing, Lab Services, Health Information, Risk Assessment
Total Rating 62
Risk 87
Buy Signal 0.22
Diagnostics & Research +11.6
Health Care Services +2.5
Market Cap: 21,749m
Avg Trading Vol: 155M USD
ATR: 2.21%
Peers RS (IBD): 71.7
Risk 5d forecast
Volatility21.5%
Rel. Tail Risk-13.6%
Reward TTM
Sharpe Ratio0.64
Alpha12.31
Character TTM
Beta0.194
Beta Downside0.423
Drawdowns 3y
Max DD17.24%
CAGR/Max DD0.81
EPS (Earnings per Share) EPS (Earnings per Share) of DGX over the last years for every Quarter: "2021-03": 3.76, "2021-06": 3.18, "2021-09": 3.96, "2021-12": 3.33, "2022-03": 3.22, "2022-06": 2.36, "2022-09": 2.36, "2022-12": 1.98, "2023-03": 2.04, "2023-06": 2.3, "2023-09": 2.22, "2023-12": 2.15, "2024-03": 2.04, "2024-06": 2.35, "2024-09": 2.3, "2024-12": 2.23, "2025-03": 2.21, "2025-06": 2.62, "2025-09": 2.6, "2025-12": 2.42, "2026-03": 0,
EPS CAGR: -47.77%
EPS Trend: -33.1%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of DGX over the last years for every Quarter: 2021-03: 2720, 2021-06: 2550, 2021-09: 2774, 2021-12: 2744, 2022-03: 2611, 2022-06: 2453, 2022-09: 2486, 2022-12: 2333, 2023-03: 2331, 2023-06: 2338, 2023-09: 2295, 2023-12: 2288, 2024-03: 2366, 2024-06: 2397, 2024-09: 2488, 2024-12: 2621, 2025-03: 2652, 2025-06: 2761, 2025-09: 2816, 2025-12: 2806, 2026-03: null,
Rev. CAGR: 1.94%
Rev. Trend: 62.2%
Last SUE: 1.63
Qual. Beats: 3
Description: DGX Quest Diagnostics

Quest Diagnostics (DGX) provides diagnostic testing and related services across the United States and internationally. The company offers a range of services, including routine and advanced clinical testing, and anatomic pathology. The diagnostic testing sector is a critical component of healthcare, providing essential information for disease diagnosis and treatment.

DGX operates under its primary Quest Diagnostics brand, alongside specialized brands like AmeriPath and Dermpath Diagnostics. Their business model involves delivering services to a diverse client base, including physicians, hospitals, health plans, and pharmaceutical companies. This broad client base is typical for large diagnostic service providers.

The company also offers risk assessment services for the life insurance industry and IT solutions for healthcare organizations. DGX leverages a wide network of laboratories, patient service centers, and mobile phlebotomists to deliver its services. Investors should conduct further research, which can be facilitated by platforms like ValueRay.

Headlines to Watch Out For
  • Testing volume directly impacts revenue growth
  • Reimbursement rates from insurers affect profitability
  • Regulatory changes in healthcare sector pose risks
  • Competition from other diagnostic providers pressures pricing
Piotroski VR‑10 (Strict) 7.5
Net Income: 992.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.75 > 1.0
NWC/Revenue: 0.91% < 20% (prev 2.26%; Δ -1.35% < -1%)
CFO/TA 0.12 > 3% & CFO 1.89b > Net Income 992.0m
Net Debt (6.50b) to EBITDA (2.03b): 3.20 < 3
Current Ratio: 1.04 > 1.5 & < 3
Outstanding Shares: last quarter (112.0m) vs 12m ago -0.88% < -2%
Gross Margin: 33.25% > 18% (prev 0.33%; Δ 3.29k% > 0.5%)
Asset Turnover: 68.16% > 50% (prev 61.12%; Δ 7.05% > 0%)
Interest Coverage Ratio: 5.31 > 6 (EBITDA TTM 2.03b / Interest Expense TTM 274.0m)
Altman Z'' 3.82
A: 0.01 (Total Current Assets 2.38b - Total Current Liabilities 2.28b) / Total Assets 16.23b
B: 0.62 (Retained Earnings 9.99b / Total Assets 16.23b)
C: 0.09 (EBIT TTM 1.46b / Avg Total Assets 16.19b)
D: 1.12 (Book Value of Equity 9.97b / Total Liabilities 8.94b)
Altman-Z'' Score: 3.82 = AA
Beneish M -3.04
DSRI: 0.97 (Receivables 1.41b/1.30b, Revenue 11.04b/9.87b)
GMI: 0.99 (GM 33.25% / 32.86%)
AQI: 0.99 (AQ_t 0.68 / AQ_t-1 0.68)
SGI: 1.12 (Revenue 11.04b / 9.87b)
TATA: -0.06 (NI 992.0m - CFO 1.89b) / TA 16.23b)
Beneish M-Score: -3.04 (Cap -4..+1) = AA
What is the price of DGX shares? As of April 02, 2026, the stock is trading at USD 195.98 with a total of 1,268,621 shares traded.
Over the past week, the price has changed by +0.63%, over one month by -5.97%, over three months by +14.27% and over the past year by +18.95%.
Is DGX a buy, sell or hold? Quest Diagnostics has received a consensus analysts rating of 3.89. Therefore, it is recommended to buy DGX.
  • StrongBuy: 8
  • Buy: 1
  • Hold: 10
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the DGX price?
Wallstreet Target Price 218.5 11.5%
Analysts Target Price 218.5 11.5%
DGX Fundamental Data Overview as of 31 March 2026
P/E Trailing = 22.3185
P/E Forward = 18.3824
P/S = 1.9709
P/B = 2.992
P/EG = 1.5581
Revenue TTM = 11.04b USD
EBIT TTM = 1.46b USD
EBITDA TTM = 2.03b USD
Long Term Debt = 5.17b USD (from longTermDebt, last quarter)
Short Term Debt = 678.0m USD (from shortTermDebt, last quarter)
Debt = 6.92b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.50b USD (from netDebt column, last quarter)
Enterprise Value = 28.25b USD (21.75b + Debt 6.92b - CCE 420.0m)
Interest Coverage Ratio = 5.31 (Ebit TTM 1.46b / Interest Expense TTM 274.0m)
EV/FCF = 20.79x (Enterprise Value 28.25b / FCF TTM 1.36b)
FCF Yield = 4.81% (FCF TTM 1.36b / Enterprise Value 28.25b)
FCF Margin = 12.32% (FCF TTM 1.36b / Revenue TTM 11.04b)
Net Margin = 8.99% (Net Income TTM 992.0m / Revenue TTM 11.04b)
Gross Margin = 33.25% ((Revenue TTM 11.04b - Cost of Revenue TTM 7.37b) / Revenue TTM)
Gross Margin QoQ = 32.57% (prev 33.70%)
Tobins Q-Ratio = 1.74 (Enterprise Value 28.25b / Total Assets 16.23b)
Interest Expense / Debt = 0.92% (Interest Expense 64.0m / Debt 6.92b)
Taxrate = 24.04% (81.0m / 337.0m)
NOPAT = 1.11b (EBIT 1.46b * (1 - 24.04%))
Current Ratio = 1.04 (Total Current Assets 2.38b / Total Current Liabilities 2.28b)
Debt / Equity = 0.96 (Debt 6.92b / totalStockholderEquity, last quarter 7.17b)
Debt / EBITDA = 3.20 (Net Debt 6.50b / EBITDA 2.03b)
Debt / FCF = 4.78 (Net Debt 6.50b / FCF TTM 1.36b)
Total Stockholder Equity = 7.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.13% (Net Income 992.0m / Total Assets 16.23b)
RoE = 13.88% (Net Income TTM 992.0m / Total Stockholder Equity 7.15b)
RoCE = 11.82% (EBIT 1.46b / Capital Employed (Equity 7.15b + L.T.Debt 5.17b))
RoIC = 8.56% (NOPAT 1.11b / Invested Capital 12.92b)
WACC = 5.22% (E(21.75b)/V(28.67b) * Re(6.66%) + D(6.92b)/V(28.67b) * Rd(0.92%) * (1-Tc(0.24)))
Discount Rate = 6.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -81.65 | Cagr: -0.44%
[DCF] Terminal Value 86.96% ; FCFF base≈1.18b ; Y1≈1.26b ; Y5≈1.52b
[DCF] Fair Price = 348.4 (EV 44.78b - Net Debt 6.50b = Equity 38.28b / Shares 109.9m; r=6.0% [WACC]; 5y FCF grow 7.41% → 3.0% )
EPS Correlation: -33.06 | EPS CAGR: -47.77% | SUE: -4.0 | # QB: 0
Revenue Correlation: 62.17 | Revenue CAGR: 1.94% | SUE: 1.63 | # QB: 3
EPS next Quarter (2026-06-30): EPS=2.86 | Chg7d=+0.027 | Chg30d=+0.117 | Revisions Net=+8 | Analysts=13
EPS current Year (2026-12-31): EPS=10.64 | Chg7d=+0.000 | Chg30d=+0.013 | Revisions Net=+9 | Growth EPS=+8.0% | Growth Revenue=+6.6%
EPS next Year (2027-12-31): EPS=11.48 | Chg7d=+0.000 | Chg30d=+0.023 | Revisions Net=+8 | Growth EPS=+7.9% | Growth Revenue=+3.7%
[Analyst] Revisions Ratio: +0.80 (9 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.4% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +3.7% (Analyst 7.2% - Implied 3.4%)
External Resources
Dataroma Stockcircle